Baird Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $148
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $140 to $148.
August 04, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst maintains an Outperform rating on Neurocrine Biosciences and raises the price target from $140 to $148, indicating a positive outlook for the stock.
The raised price target by Baird analyst indicates a positive outlook for Neurocrine Biosciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100